Concomitant phase II studies of pyrazofurin and razoxane in alkylating agent-resistant cases of epithelial ovarian carcinoma. 1981

J H Edmonson, and D G Decker, and G D Malkasian, and M J Webb

UI MeSH Term Description Entries
D007970 Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000). Leukocytopenia,Leukocytopenias,Leukopenias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009325 Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011929 Razoxane An antimitotic agent with immunosuppressive properties. ICRF-159,ICRF-186,NSC-129943,Razoxane Mesylate, (R)-Isomer,Razoxane, (R)-Isomer,Razoxin,ICRF 159,ICRF 186,ICRF159,ICRF186,NSC 129943,NSC129943
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females

Related Publications

J H Edmonson, and D G Decker, and G D Malkasian, and M J Webb
November 1978, Cancer,
J H Edmonson, and D G Decker, and G D Malkasian, and M J Webb
January 1979, Cancer treatment reports,
J H Edmonson, and D G Decker, and G D Malkasian, and M J Webb
April 1984, Cancer,
J H Edmonson, and D G Decker, and G D Malkasian, and M J Webb
January 1977, Cancer treatment reports,
J H Edmonson, and D G Decker, and G D Malkasian, and M J Webb
December 1980, Gynecologic oncology,
J H Edmonson, and D G Decker, and G D Malkasian, and M J Webb
January 1979, Cancer treatment reports,
J H Edmonson, and D G Decker, and G D Malkasian, and M J Webb
March 1978, Cancer treatment reports,
J H Edmonson, and D G Decker, and G D Malkasian, and M J Webb
January 1989, Cancer chemotherapy and pharmacology,
J H Edmonson, and D G Decker, and G D Malkasian, and M J Webb
August 1977, Cancer treatment reports,
J H Edmonson, and D G Decker, and G D Malkasian, and M J Webb
February 1989, Gynecologic oncology,
Copied contents to your clipboard!